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Aims
Turner syndrome (TS) is a sex-chromosome abnormality
in females resulting from partial or complete absence of
one of the X chromosomes [1]. One of the main features
of TS is short stature. Final height in short girls with TS
improves with growth hormone treatment [2]. The aim of
this study was to assess the effectiveness of growth hor-
mone therapy in a cohort of Malaysian patients with TS.
Methods
Data from the electronic medical records of 20 patients
with TS treated with growth hormone in Putrajaya Hos-
pital, Malaysia from the year 2005 to 2014 was analysed.
Results
The mean age of initiation of therapy was 11.5 ± 3.4 and
55.0% were started after the age of 12 years. The mean
height standard deviation score (SDS) increased from
-3.84 (±0.94) SD at study entry to -3.47 (±0.97) SD at the
end of the first year. This improvement was seen with
subsequent year of treatment, though the degree of
change in height SDS reduced with time. Age of initiation
of therapy had a bearing on treatment response as those
who had received growth hormone at an earlier age
experienced better growth response. 75.0% of patients
who achieved final height were able to achieve the final
height within the target height. Of the patients who
achieved final height, mean age of puberty was 16 ± 1.5
years and mean height SDS at onset of puberty was
-3.3SD. There were no reported adverse events.
Conclusion
Growth hormone therapy improved growth profile of
Malaysian children with TS and the importance of early
initiation of therapy is demonstrated in this study.
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